

William Anderson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1201411/publications.pdf>

Version: 2024-02-01

108
papers

4,061
citations

117625

34
h-index

138484

58
g-index

111
all docs

111
docs citations

111
times ranked

5688
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term kidney function in children with Wilms tumour and constitutional WT1 pathogenic variant. <i>Pediatric Nephrology</i> , 2022, 37, 821-832.	1.7	5
2	Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours. <i>European Journal of Cancer</i> , 2022, 162, 209-220.	2.8	12
3	A Simple and Robust Single-Step Method for CAR-VÎ1 Î³ÎT Cell Expansion and Transduction for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	16
4	ATRT-20. Novel prognostic molecular signatures for improved risk-classification of Atypical Teratoid Rhabdoid Tumours. <i>Neuro-Oncology</i> , 2022, 24, i7-i7.	1.2	0
5	Fluorescence imaging in pediatric surgery: State-of-the-art and future perspectives. <i>Journal of Pediatric Surgery</i> , 2021, 56, 655-662.	1.6	35
6	Importance of Magnetic Resonance Imaging With Diffusion-weighted Imaging in Guiding Biopsy of Nodular Ganglioneuroblastoma: A Case Report. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e130-e135.	0.6	2
7	Tumor to normal single-cell mRNA comparisons reveal a pan-neuroblastoma cancer cell. <i>Science Advances</i> , 2021, 7, .	10.3	78
8	Combined Effects of Myeloid Cells in the Neuroblastoma Tumor Microenvironment. <i>Cancers</i> , 2021, 13, 1743.	3.7	7
9	Near-InfraRed PhotoImmunoTherapy (NIR-PIT) for the local control of solid cancers: Challenges and potentials for human applications. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 161, 103325.	4.4	15
10	Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment. <i>Blood</i> , 2021, 137, 2992-2997.	1.4	19
11	Novel Treatments and Technologies Applied to the Cure of Neuroblastoma. <i>Children</i> , 2021, 8, 482.	1.5	12
12	Alcohol-abuse drug disulfiram targets pediatric glioma via MLL degradation. <i>Cell Death and Disease</i> , 2021, 12, 785.	6.3	11
13	Flow cytometry of bone marrow aspirates from neuroblastoma patients is a highly sensitive technique for quantification of low-level neuroblastoma. <i>F1000Research</i> , 2021, 10, 947.	1.6	0
14	Antitumor activity without on-target off-tumor toxicity of GD2â€chimeric antigen receptor T cells in patients with neuroblastoma. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	108
15	Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity. <i>Nature Communications</i> , 2020, 11, 4324.	12.8	75
16	Engineering Solutions for Mitigation of Chimeric Antigen Receptor T-Cell Dysfunction. <i>Cancers</i> , 2020, 12, 2326.	3.7	6
17	Lineage-Independent Tumors in Bilateral Neuroblastoma. <i>New England Journal of Medicine</i> , 2020, 383, 1860-1865.	27.0	23
18	Noninvasive MRI Native T1 Mapping Detects Response to MYCN-targeted Therapies in the Th-MYCN Model of Neuroblastoma. <i>Cancer Research</i> , 2020, 80, 3424-3435.	0.9	15

#	ARTICLE	IF	CITATIONS
19	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 52-66.	2.8	52
20	Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function. <i>PLoS ONE</i> , 2019, 14, e0216373.	2.5	19
21	Engineered human mesenchymal stem cells for neuroblastoma therapeutics. <i>Oncology Reports</i> , 2019, 42, 35-42.	2.6	12
22	Engineering $\gamma\delta$ T cells limits tonic signaling associated with chimeric antigen receptors. <i>Science Signaling</i> , 2019, 12, .	3.6	29
23	A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. <i>European Journal of Cancer</i> , 2019, 121, 224-235.	2.8	44
24	MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment. <i>Cancer Research</i> , 2019, 79, 2978-2991.	0.9	13
25	Identification of new Wilms tumour predisposition genes: an exome sequencing study. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 322-331.	5.6	82
26	<i>In Vivo</i> Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis. <i>Cancer Research</i> , 2019, 79, 5382-5393.	0.9	42
27	Embryonal precursors of Wilms tumor. <i>Science</i> , 2019, 366, 1247-1251.	12.6	101
28	The presence of Y674/Y675 phosphorylated NTRK1 via TP53 repression of PTPN6 expression as a potential prognostic marker in neuroblastoma. <i>Human Pathology</i> , 2019, 86, 182-192.	2.0	6
29	Establishment and phenotyping of neurosphere cultures from primary neuroblastoma samples. <i>F1000Research</i> , 2019, 8, 823.	1.6	10
30	Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation. <i>Molecular Therapy</i> , 2018, 26, 354-365.	8.2	185
31	Antibody based therapy for childhood solid cancers. <i>Current Opinion in Chemical Engineering</i> , 2018, 19, 153-162.	7.8	1
32	Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 1409.	4.8	55
33	Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants. <i>Nature Communications</i> , 2018, 9, 2378.	12.8	72
34	Adoptive T Cell Therapies for Children's Cancers. , 2018, , 161-174.		0
35	Developing immunotherapies for childhood cancer. <i>Archives of Disease in Childhood: Education and Practice Edition</i> , 2017, 102, 162-165.	0.5	5
36	Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor. <i>Molecular Therapy</i> , 2017, 25, 1234-1247.	8.2	69

#	ARTICLE	IF	CITATIONS
37	Unleashing the immune response against childhood solid cancers. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26548.	1.5	6
38	An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers. <i>PLoS ONE</i> , 2016, 11, e0152196.	2.5	57
39	Post-thaw viability of cryopreserved peripheral blood stem cells (<sc>PBSC</sc>) does not guarantee functional activity: important implications for quality assurance of stem cell transplant programmes. <i>British Journal of Haematology</i> , 2016, 174, 942-951.	2.5	35
40	A Promyelocytic Leukemia Protein- α Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma. <i>Clinical Cancer Research</i> , 2016, 22, 3398-3409.	7.0	8
41	Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with V β 3V β 2+ α T cells. <i>Oncolmmunology</i> , 2016, 5, e1025194.	4.6	27
42	Abstract B128: Chimeric antigen receptor transduced gamma delta T lymphocytes provide enhanced tumor specificity. , 2016, , .		0
43	Adoptive T-Cell Therapy for Cancer in the United Kingdom: A Review of Activity for the British Society of Gene and Cell Therapy Annual Meeting 2015. <i>Human Gene Therapy</i> , 2015, 26, 276-285.	2.7	17
44	The Brn-3b transcription factor regulates the growth, behavior, and invasiveness of human neuroblastoma cells in vitro and in vivo.. <i>Journal of Biological Chemistry</i> , 2015, 290, 888.	3.4	1
45	Non-V delta 2 gamma delta T lymphocytes as effectors of cancer immunotherapy. <i>Oncolmmunology</i> , 2015, 4, e973808.	4.6	14
46	Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity. <i>Cancer Research</i> , 2015, 75, 3043-3053.	0.9	78
47	A Pathogenic Mosaic TP53 Mutation in Two Germ Layers Detected by Next Generation Sequencing. <i>PLoS ONE</i> , 2014, 9, e96531.	2.5	27
48	α T cells for cancer immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e27572.	4.6	158
49	Distant Metastatic Spread of Molecularly Proven Infantile Fibrosarcoma of the Chest in a 2-month-old Girl. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, 231-233.	0.6	9
50	Neuroblastoma Killing Properties of V β 2 and V β 2-Negative α T Cells Following Expansion by Artificial Antigen-Presenting Cells. <i>Clinical Cancer Research</i> , 2014, 20, 5720-5732.	7.0	99
51	Regeneration of stalled immune responses to transformed and infected cells using α T cells. <i>Drug Discovery Today</i> , 2014, 19, 787-793.	6.4	4
52	Tumor-Associated Antigen Presentation by α T-Cells in Cancer Immunotherapy. <i>Blood</i> , 2014, 124, 1411-1411.	1.4	1
53	Abstract LB-328: SHP-1, p53 and Y674/Y675-phosphorylated-trkA: a molecular pathway and prognostic marker for neuroblastoma. , 2014, , .		0
54	New Strategies in Neuroblastoma: Therapeutic Targeting of MYCN and ALK. <i>Clinical Cancer Research</i> , 2013, 19, 5814-5821.	7.0	119

#	ARTICLE	IF	CITATIONS
55	Polyphenol E Enhances the Antitumor Immune Response in Neuroblastoma by Inactivating Myeloid Suppressor Cells. <i>Clinical Cancer Research</i> , 2013, 19, 1116-1125.	7.0	74
56	Persistent Complete Response After Single-agent Sunitinib Treatment in a Case of TFE Translocation Positive Relapsed Metastatic Pediatric Renal Cell Carcinoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, e1-e3.	0.6	24
57	Catechins and antitumor immunity. <i>Oncolmmunology</i> , 2013, 2, e24443.	4.6	8
58	The immune environment of paediatric solid malignancies: evidence from an immunohistochemical study of clinical cases. <i>Fetal and Pediatric Pathology</i> , 2013, 32, 298-307.	0.7	16
59	STAT3 Regulates Proliferation and Immunogenicity of the Ewing Family of Tumors In Vitro. <i>Sarcoma</i> , 2012, 2012, 1-6.	1.3	10
60	Human $\hat{I}^3\hat{I}$ T Lymphocytes Are Licensed for Professional Antigen Presentation by Interaction with Opsonized Target Cells. <i>Journal of Immunology</i> , 2012, 188, 1708-1716.	0.8	119
61	Licensing of $\hat{I}^3\hat{I}$ T cells for professional antigen presentation. <i>Oncolmmunology</i> , 2012, 1, 1652-1654.	4.6	14
62	Congenital malignant rhabdoid tumor of the scalp. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2012, 40, e258-e260.	1.7	8
63	Licensing of killer dendritic cells in mouse and humans: Functional similarities between IKDC and human blood $\hat{I}^3\hat{I}$ T-lymphocytes. <i>Journal of Immunotoxicology</i> , 2012, 9, 259-266.	1.7	6
64	Characterisation and Validation of Insertions and Deletions in 173 Patient Exomes. <i>PLoS ONE</i> , 2012, 7, e51292.	2.5	8
65	Inflammation: What role in pediatric cancer?. <i>Pediatric Blood and Cancer</i> , 2012, 58, 659-664.	1.5	8
66	Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma. <i>Clinical and Translational Oncology</i> , 2012, 14, 271-279.	2.4	60
67	Pilot study of F18-Fluorodeoxyglucose Positron Emission Tomography/computerised tomography in Wilms's™ tumour: Correlation with conventional imaging, pathology and immunohistochemistry. <i>European Journal of Cancer</i> , 2011, 47, 389-396.	2.8	40
68	Brain lipid-binding protein: a marker of differentiation in neuroblastic tumors. <i>Journal of Pediatric Surgery</i> , 2011, 46, 1197-1200.	1.6	6
69	Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2-Deoxycytidine. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1243-1255.	4.2	27
70	Patterns of shift in ADC distributions in abdominal tumours during chemotherapy feasibility study. <i>Pediatric Radiology</i> , 2011, 41, 99-106.	2.0	43
71	Malignant rhabdoid tumors: A familial condition?. <i>Pediatric Blood and Cancer</i> , 2011, 56, 1-2.	1.5	3
72	The RAC specific guanine nucleotide exchange factor Asef functions downstream from TEL-AML1 to promote leukaemic transformation. <i>Leukemia Research</i> , 2010, 34, 109-115.	0.8	4

#	ARTICLE	IF	CITATIONS
73	A novel small-molecule inhibitor of IL-6 signalling. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 7029-7032.	2.2	16
74	Clinical and pathological features of paediatric malignant rhabdoid tumours. <i>Pediatric Blood and Cancer</i> , 2010, 54, 29-34.	1.5	65
75	PAX5 Expression in Nonhematopoietic Tissues. <i>American Journal of Clinical Pathology</i> , 2010, 133, 407-415.	0.7	22
76	Migratory and Antigen Presentation Functions of IFN-Producing Killer Dendritic Cells. <i>Cancer Research</i> , 2009, 69, 6598-6606.	0.9	14
77	Clusterin, a Haploinsufficient Tumor Suppressor Gene in Neuroblastomas. <i>Journal of the National Cancer Institute</i> , 2009, 101, 663-677.	6.3	87
78	Ultrasoundâ€­guided core needle biopsy for the diagnosis of rhabdomyosarcoma in childhood. <i>Pediatric Blood and Cancer</i> , 2009, 53, 356-360.	1.5	19
79	PAX5 Expression in Rhabdomyosarcoma. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1575-1577.	3.7	12
80	MYCN as a target for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 693-700.	4.2	33
81	Rhabdomyosarcoma Subtyping by Immunohistochemical Assessment of Myogenin: Tissue Array Study and Review of the Literature. <i>Pathology and Oncology Research</i> , 2008, 14, 233-238.	1.9	27
82	Uneventful administration of vincristine in Charcotâ€­Marieâ€­Tooth disease type 1X. <i>Pediatric Blood and Cancer</i> , 2008, 50, 874-876.	1.5	12
83	Bone Marrow-Derived IFN-Producing Killer Dendritic Cells Account for the Tumoricidal Activity of Unpulsed Dendritic Cells. <i>Journal of Immunology</i> , 2008, 181, 6654-6663.	0.8	21
84	Development of Cellular Immune Responses against PAX5, a Novel Target for Cancer Immunotherapy. <i>Cancer Research</i> , 2008, 68, 8058-8065.	0.9	17
85	B-MYB is hypophosphorylated and resistant to degradation in neuroblastoma: Implications for cell survival. <i>Blood Cells, Molecules, and Diseases</i> , 2007, 39, 263-271.	1.4	11
86	IMMUNOHISTOCHEMICAL NUCLEAR POSITIVITY FOR WT1 IN CHILDHOOD ACUTE MYELOID LEUKEMIA. <i>Fetal and Pediatric Pathology</i> , 2007, 26, 193-197.	0.7	7
87	Development of anti-PAX3 immune responses; a target for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1381-1395.	4.2	11
88	The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas. <i>Growth Factors</i> , 2006, 24, 197-208.	1.7	38
89	PAX3-FKHR Chimeric Oncoprotein: Hiding Itself from Immune Detection?. <i>Cell Cycle</i> , 2006, 5, 563-564.	2.6	1
90	Rapid and accurate determination of MYCN copy number and 1p deletion in neuroblastoma by quantitative PCR. <i>Pediatric Blood and Cancer</i> , 2006, 46, 820-824.	1.5	9

#	ARTICLE	IF	CITATIONS
91	MYCNderegulation as a potential target for novel therapies in rhabdomyosarcoma. Expert Review of Anticancer Therapy, 2006, 6, 217-224.	2.4	15
92	Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood, 2005, 105, 2510-2518.	1.4	165
93	Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein. Journal of Experimental Medicine, 2005, 202, 1399-1410.	8.5	53
94	Relationship Between MYCN Copy Number and Expression in Rhabdomyosarcomas and Correlation With Adverse Prognosis in the Alveolar Subtype. Journal of Clinical Oncology, 2005, 23, 880-888.	1.6	106
95	A molecular map of mesenchymal tumors. Genome Biology, 2005, 6, R76.	9.6	119
96	The Brn-3b Transcription Factor Regulates the Growth, Behavior, and Invasiveness of Human Neuroblastoma Cells in Vitro and in Vivo. Journal of Biological Chemistry, 2004, 279, 21617-21627.	3.4	35
97	Chromosomal imbalances in pleomorphic rhabdomyosarcomas and identification of the alveolar rhabdomyosarcoma-associated PAX3-FOXO1A fusion gene in one case. Cancer Genetics and Cytogenetics, 2003, 140, 73-77.	1.0	35
98	Response Without Shrinkage in Bilateral Wilms Tumor: Significance of Rhabdomyomatous Histology. Journal of Pediatric Hematology/Oncology, 2002, 24, 31-34.	0.6	40
99	PAX3-FKHR Induces Morphological Change and Enhances Cellular Proliferation and Invasion in Rhabdomyosarcoma. American Journal of Pathology, 2001, 159, 1089-1096.	3.8	67
100	Cytogenetic abnormalities in 42 rhabdomyosarcoma: A United Kingdom cancer cytogenetics group study. Medical and Pediatric Oncology, 2001, 36, 259-267.	1.0	70
101	Cytogenetic abnormalities in 42 rhabdomyosarcoma: A United Kingdom cancer cytogenetics group study. Medical and Pediatric Oncology, 2001, 36, 259-267.	1.0	3
102	A novel and consistent amplicon at 13q31 associated with alveolar rhabdomyosarcoma. , 2000, 28, 220-226.		75
103	Genes, chromosomes, and rhabdomyosarcoma. Genes Chromosomes and Cancer, 1999, 26, 275-285.	2.8	145
104	Disruption of Imprinted Genes at Chromosome Region 11p15.5 in Paediatric Rhabdomyosarcoma. Neoplasia, 1999, 1, 340-348.	5.3	85
105	Novel formation and amplification of thePAX7-FKHR fusion gene in a case of alveolar rhabdomyosarcoma. , 1996, 17, 7-13.		50
106	OSTEOGENESIS IMPERFECTA IS LINKED TO BOTH TYPE I COLLAGEN STRUCTURAL GENES. Lancet, The, 1986, 328, 69-72.	13.7	193
107	Augmenting human gamma delta lymphocytes for cancer therapy with chimeric antigen receptors. Exploration of Immunology, 0, , 168-179.	0.3	3
108	Flow cytometry of bone marrow aspirates from neuroblastoma patients is a highly sensitive technique for quantification of low-level neuroblastoma. F1000Research, 0, 10, 947.	1.6	2